topotecan has been researched along with staurosporine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basi, GS; Earnshaw, WC; Eischen, CM; Kaufmann, SH; Kottke, TJ; Leibson, PJ; Martins, LM; Tung, JS | 1 |
| Albig, W; Doenecke, D; Hanecke, K; Kratzmeier, M | 1 |
| Daoud, SS; Meadows, GG; Redkar, AA | 1 |
| Fujita, N; Tsuruo, T | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Daoud, SS; Mixter, P; Redkar, A | 1 |
| Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW | 1 |
| Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S | 1 |
| Karp, J | 1 |
| Chen, AP; Doroshow, JH; Kummar, S; Nguyen, D; Pommier, Y; Rubinstein, L; Tomaszewski, JE; Voeller, D; Yang, SX; Zajac-Kaye, M | 1 |
2 trial(s) available for topotecan and staurosporine
| Article | Year |
|---|---|
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan | 2006 |
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan | 2007 |
8 other study(ies) available for topotecan and staurosporine
| Article | Year |
|---|---|
Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.
Topics: Affinity Labels; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biotin; Camptothecin; Caspase 3; Caspase 7; Caspases; Cisplatin; Cysteine Endopeptidases; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Lamin Type B; Lamins; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Methotrexate; Neoplasm Proteins; Nuclear Proteins; Oligopeptides; Poly(ADP-ribose) Polymerases; Staurosporine; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1997 |
Rapid dephosphorylation of H1 histones after apoptosis induction.
Topics: Apoptosis; Deoxyribonucleases; DNA Fragmentation; DNA, Neoplasm; Enzyme Activation; Histones; HL-60 Cells; Humans; Marine Toxins; Nucleosomes; Oxazoles; Phosphoprotein Phosphatases; Phosphorylation; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Topotecan | 2000 |
UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.
Topics: Alkaloids; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Marrow Cells; Bromodeoxyuridine; Camptothecin; Cell Division; Colony-Forming Units Assay; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Immunoenzyme Techniques; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Protein Kinase C; Staurosporine; Topoisomerase I Inhibitors; Topotecan | 2001 |
Survival-signaling pathway as a promising target for cancer chemotherapy.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Alkaloids; Animals; Antineoplastic Agents; Blotting, Western; Cell Survival; DNA, Complementary; Drug Design; Enzyme Inhibitors; Gene Expression; HSP90 Heat-Shock Proteins; Humans; Protein Kinase C; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine; Topotecan; Tumor Cells, Cultured | 2003 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Epithelial Cells; Female; Genes, p53; Humans; Staurosporine; Topotecan; Tumor Cells, Cultured | 2004 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Checkpoints; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA Repair; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Staurosporine; Time Factors; Topotecan; Tumor Suppressor Protein p53 | 2011 |